However, bladder cancer with NEIL2 CNV alterations and mutations was trending toward decreased OS, and those with RRM2B CNV alterations showed a non-significant decrease in OS in colorectal, esophageal, and head and neck squamous cell carcinoma and a non-significant decreased DFS in bladder, lung adenocarcinoma, and CRC (data not shown). This evidence concerns the gene RRM2B and urinary bladder cancer.